Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule [Yahoo! Finance]
Monopar Therapeutics Inc. (MNPR)
Company Research
Source: Yahoo! Finance
innovative treatments for cancer patients, today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) as a result of the closing bid price of the Company's common stock being $1.00 per share or greater for 10 consecutive trading sessions. The Company is now compliant with the minimum bid price listing standard for continued Nasdaq listing. About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, Phase 1-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers, as well as early development stage programs against solid cancers. For more information, visit: www.monopartx.com. CONTACT: Monopar Therapeutics Inc. Investor Relations Karthi
Show less
Read more
Impact Snapshot
Event Time:
MNPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNPR alerts
High impacting Monopar Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
MNPR
News
- Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-ZrGlobeNewswire
- Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
- Monopar Regains Compliance with Nasdaq Minimum Bid Price RuleGlobeNewswire
- Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced CancersGlobeNewswire
- Monopar Therapeutics Inc. (NASDAQ: MNPR) had its price target raised by analysts at HC Wainwright from $2.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
MNPR
Sec Filings
- 9/12/24 - Form 8-K
- 8/27/24 - Form 8-K
- 8/21/24 - Form 8-K
- MNPR's page on the SEC website